Michael G Hanna
Vaccinogen Inc., USA
Posters-Accepted Abstracts: J Vaccines & Vaccin
While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years, the magnitude and diversity of these mutations has been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. Target therapies require targets. In this case, the targets are tumor specific or associated antigens, the proteins expressed from these somatic cell mutations. While the immunotherapeutic approach to eliminating cancer was launched with the assumption that cancer cells were homogeneous, the recent genomic understanding of tumor cells indicates that there is both inter and intra-tumoral heterogeneity. This presentation will discuss the consequences of this new knowledge of tumor cell biology to the immunotherapeutic approach to treating cancer. What is more, this presentation will discuss the translational development of an active specific immunotherapeutic approach from preclinical to beneficial clinical benefits.
Email: mghannajr@vaccinogeninc.com